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The development of pulmonary hypertension in COPD adversely affects survival and exercise capacity and is associated with
an increased risk of severe acute exacerbations. Unfortunately not all patients with COPD who meet criteria for long term
oxygen therapy benefit from it. Even in those who benefit from long term oxygen therapy, such therapy may reverse the elevated
pulmonary artery pressure but cannot normalize it. Moreover, the recent discovery of the key roles of endothelial dysfunction and
inflammation in the pathogenesis of PH provides the rationale for considering specific pulmonary vasodilators that also possess
antiproliferative properties and statins.
1. Introduction
Pulmonary hypertension (PH) secondary to chronic ob-
structive pulmonary disease (COPD) is placed in group 3 of
the WHO classification of PH, that is, PH associated with
lung diseases and/or hypoxemia (Table 1) [1]. PH in COPD
has been variably defined as resting mean pulmonary artery
pressure (mPAP) > 20–25 mm Hg. PH in COPD adversely
affects survival and exercise capacity and is associated with
an increased risk of acute exacerbations. Recent studies have
shown that endothelial dysfunction and systemic inflamma-
tion also play important roles in the pathogenesis of PH.
The recent development of specific pulmonary vasodilators
with antiproliferative properties has stimulated an immense
interest in studying such drugs in PH secondary to COPD.
2. Prevlence of PH in COPD
The prevalence of PH in stable COPD varies from 20 to
91% depending on the definition of PH (mPAP > 20 versus
>25 mm Hg), the severity of COPD (forced expiratory vol-
ume in the first second: FEV1), and the method of measuring
the pulmonary artery pressure (echocardiography versus
right heart catheterization) [2–7].
In severe COPD patients with or without resting PH,
steady-state exercise may raise pulmonary artery pressure
(PAP) to about twice the level of its resting value [8]. In severe
COPD activities of daily living such as climbing stairs or
walking can induce transient PH.
In patients with severe COPD, oxygen saturation may fall
during REM sleep by 20–30% [9, 10] and PAP may rise by as
much as 20 mm Hg [11].
During an acute exacerbation of COPD, PAP may rise by
as much as 20 mm Hg and return to its baseline after recovery
[12, 13].
3. Significance of PH in COPD
In the era before the widespread availability of long-term
oxygen therapy (LTOT) it was well known that the presence
of PH was associated with poor prognosis in COPD. How-
ever, even on LTOT the best prognostic factor is not the
FEV1, nor the degree of hypoxemia or hypercapnia, but the
level of mPAP. The 5-year survival rate is only 36% in patients
with initial mPAP > 25 mm Hg compared to 62% in those
with initial mPAP≤ 25 mm Hg [14]. Moreover, Weitzenblum
et al. [15], who followed up hypoxemic COPD patients with
PH on LTOT for a period of 6 years, demonstrated a reversal
but not normalization of the PAP. Recently, Zieliński et al.
[16] also reported similar findings in a larger study.
PH is also an independent predictor of exercise capacity.
Sims et al. [17] found that in 362 severe COPD patients
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Table 1: Updated clinical classification of pulmonary hypertension (Dana Point, 2008) [1].




(1.2.2) ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
(1.2.3) Unknown
(1.3) Drug- and toxin-induced
(1.4) Associated with
(1.4.1) Connective tissue diseases
(1.4.2) HIV infection
(1.4.3) Portal hypertension
(1.4.4) Congenital heart disease
(1.4.5) Schistosomiasis
(1.4.6) Chronic hemolytic anemia
(1.5) Persistent pulmonary hypertension of the newborn
(i) Pulmonary venoocclusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)




(3) Pulmonary hypertension owing to lung disease and/or hypoxia
(3.1) Chronic obstructive pulmonary disease (COPD)
(3.2) Interstitial lung disease
(3.3) Other pulmonary diseases with mixed restrictive and obstructive pattern
(3.4) Sleep-disordered breathing
(3.5) Alveolar hypoventilation disorders
(3.6) Chronic exposure to high altitude
(3.7) Developmental abnormalities
(4) Chronic thromboembolic pulmonary hypertension (CTEPH)
(5) Pulmonary hypertension with unclear multifactorial mechanisms
(5.1) Hematologic disorders: myeloproliferative disorders, splenectomy
(5.2) Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis,
neurofibromatosis, vasculitis
(5.3) Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
(5.4) Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis
Simonneau [1].
who underwent right-heart catheterization (RHC) as part
of evaluation for lung transplantation, higher pulmonary
artery pressures were associated with shorter 6-minute walk
distance (6MWD) even after controlling for demographics,
anthropomorphics, severity of airflow obstruction, and pul-
monary artery wedge pressure (PAWP). They found an 11 m
decline in 6MWD for every 5 mm rise in mPAP (95% CI
21, 0.7; P = 0.04). In another study Cuttica et al. [7] re-
viewed the records of 1154 COPD patients listed for lung
transplantation and found an association between mPAP
and 6MWD independent of lung function and PAWP (β =
−1.33; P = 0.01).
Lastly, it has been shown that a mPAP > 18 mm Hg is
associated with an increased risk of severe acute exacerbation
in patients with moderate to severe COPD [18].
4. Pathophysiology of PH Secondary to COPD
In hemodynamic terms PAP depends upon cardiac output
(CO), pulmonary vascular resistance (PVR), and pulmonary
artery wedge pressure (PAWP) (Figure 1). Resting PH in
COPD results predominantly from an elevated PVR whereas
PH during exercise results predominantly from an increase
in CO in the face of a relatively “fixed” PVR, that is, there is
reduced recruitability and distensibility of pulmonary vessels
[19]. Hyperinflation increases PVR [20] as well as PAWP [20,
21] and PAP [20], particularly during exercise.
Traditionally, elevated PVR in COPD has been consid-
ered to be the consequence of hypoxic pulmonary vaso-
constriction and vascular remodeling, destruction of the pul-
monary vascular bed by emphysema, polycythemia, and hy-
perinflation. Recently, it has been recognized that endothelial
dysfunction and systemic inflammation also play key roles in
the pathogenesis of PH (Figure 2). In fact it is believed that
the initial event in the natural history of PH in COPD could
be endothelial dysfunction caused by cigarette smoke [22].
4.1. Pulmonary Vasoconstriction. Hypoxic constriction of
the small muscular pulmonary arteries [23] is a protective
mechanism to divert blood flow from hypoxic alveoli to
Pulmonary Medicine 3
mPAP − PAWP = CO × PVR










(4) Destruction of vascular bed
pleural and juxtacardiac
Auto-PEEP
Figure 1: Pathophysiology of PH in COPD. mPAP: mean pulmonary artery pressure, PAWP: pulmonary artery wedge pressure, CO: cardiac
output, PVR: pulmonary vascular resistance, PEEP: positive end-expiratory pressure.
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Figure 2: Pathophysiology of elevated PVR in COPD. PVR: pulmonary vascular resistance, NO: nitric oxide, PG: prostaglandin, ET-1:
endothelin-1.
better ventilated alveoli and reduce ventilation-perfusion
mismatch [24]. However, when alveolar hypoxia is diffuse,
such as in severe COPD, it causes generalized pulmonary vas-
oconstriction and consequently raises the PVR. Persistent
hypoxia leads to pulmonary vascular remodeling [25] which
contributes to the PVR.
4.2. Pulmonary Vascular Remodeling. Vascular remodeling in
COPD patients is seen at all stages of the disease and is char-
acterized by intimal fibrosis and proliferation of longitudinal
smooth muscle in the muscular pulmonary arteries and arte-
rioles, and neomuscularization of pulmonary arterioles [26–
28]. These pulmonary vascular changes also occur in patients
with mild COPD and no hypoxia and in smokers with no
airway obstruction. This suggests that mechanisms other
than hypoxia also play an important role in the pathogenesis
of vascular remodeling [29].
However, pathologic studies in COPD have not shown
complex lesions, which are frequently encountered in pa-
tients with pulmonary arterial hypertension [30], such as
plexiform lesions (irregular mass of endothelial cells) or
angiomatoid lesions, characteristic of severe PH.
4.3. Endothelial Dysfunction. The normal endothelium plays
an important role in modulating pulmonary vasomotor tone
and cellular proliferation. Nitric oxide (NO) produced by
endothelial NO synthase (eNOS) has vasodilator and anti-
proliferative properties. Prostacyclin produced by the activity
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of prostacyclin synthase is another vasodilator that also pro-
tects against vascular remodeling. Countering vasodilatation
is endothelium-derived endothelin-1 (ET-1). Endothelial
dysfunction caused by smoking, products of inflammation,
hypoxia, and shear stress results in altered production of
these mediators of tone and/or proliferation, and conse-
quently pulmonary vasoconstriction and vascular remodel-
ing with the latter perpetuating endothelial dysfunction and
creating a vicious cycle. In patients with COPD and PH
there is a reduction in the synthesis and/or release of NO
from the lung [31]. In COPD there is a reduction in the
expression of prostacyclin synthase mRNA [32], and in
patients with secondary pulmonary hypertension there is an
excessive expression of endothelin-1 (ET-1) [33]. Arterial
ET-1 also increases shortly after episodes of nocturnal oxygen
desaturation in patients with COPD and remains higher
during the day in these subjects [34].
4.4. Inflammation. Cigarette smoking induces a CD8+ T-
lymphocyte infiltration of the adventitia of muscular pul-
monary arteries, which correlates with both the endotheli-
um-dependent relaxation and the intimal thickness, suggest-
ing the potential involvement of an inflammatory process in
the pathogenesis of pulmonary vascular abnormalities in the
early stage of COPD [35].
Systemic inflammation is a known component of COPD
[36, 37] and inflammation may contribute to the pathogene-
sis of PH. Chaouat et al. [38] showed that elevated circulating
levels of the proinflammatory cytokine interleukin-6 (IL-6)
directly correlated with elevations in mPAP (r = 0.39; P <
0.001). Moreover, C-reactive protein levels have also been
shown to correlate with both PAP and levels of ET-1 [39].
4.5. Destruction of the Pulmonary Vascular Bed. Destruction
of the pulmonary vascular bed by emphysema reduces the
total cross-sectional area of the pulmonary circulation and
increases the total PVR when the remaining capacitance ves-
sels are abnormal and unable to accommodate the increased
diverted pulmonary blood flow at rest and the increased CO
during exercise.
A hypercoagulable state has also been described in
patients with COPD [40, 41]. There appears to be an in-
creased frequency of deep venous thrombosis and pulmon-
ary embolism in acute exacerbations of COPD [41–43] and
histopathologically thrombotic lesions have been detected in
lung tissue from patients with severe emphysema undergoing
lung-volume reduction surgery [44]. It is postulated that the
inflammatory aspects of the so-called COPD exacerbation
may trigger a hypercoagulable state and increase the risk of
thrombosis including in situ thrombosis.
4.6. Polycythemia. Polycythemia not only increases the vis-
cosity of blood and the resistance to blood flow through
the pulmonary circulation [45] but also augments hypoxic
pulmonary vasoconstriction by causing a local deficiency
of NO which may be related to the excessive removal of
NO from the pulmonary circulation by the large amount of
hemoglobin [46, 47].
4.7. Genetic Factors. The pulmonary vascular response to
hypoxia is genetically determined. Serotonin (5-hydroxy-
tryptamine, 5-HT) and its transporter (5-HTT) play a role in
pulmonary artery smooth muscle cell (PASMC) proliferation
and vascular remodeling. The severity of PH in hypoxic
COPD patients depends upon 5-HTT gene polymorphism.
PH is most severe in patients carrying the LL genotype,
which is associated with higher levels of 5-HTT expression
in PASMCs [48]. ACE is present in very high concentrations
in the lungs and its activity is further increased by hypoxia
[49]. ACE is a vasoconstrictor and mediator of PASMC pro-
liferation. The ACE DD genotype is associated with increased
circulating and tissue concentrations of ACE. Moreover, the
ACE DD genotype is associated with exaggerated PH during
exercise in COPD patients [50].
4.8. Hyperinflation. Severe emphysema with air-trapping
and hyperinflation is associated with intrinsic positive end-
expiratory pressure of 5–7.5 cm H2O [51]. The positive alve-
olar pressure throughout respiration contributes to the high
PVR [20] as well as increases both PAWP [20, 21] and PAP
[20]. This mechanism may assume a more important role
in development of PH during exercise and in patients with
severe emphysema who are not hypoxemic.
5. Right and Left Ventricular Function in
PH Secondary to COPD
In response to the increased PVR the right ventricle (RV)
gradually undergoes hypertrophy and dilatation-cor pul-
monale. This increase in RV end-diastolic volume (RVEDV),
that is, preload, to maintain a normal stroke volume (SV)
accounts for the reduced RV ejection fraction (EF). RV
contractility, as assessed by end systolic pressure-volume
relation, is normal in stable COPD patients and the RV oper-
ates on an extension of the normal RV function Frank-Starl-
ing curve [52].
Changes in RV SV must invariably alter left ventricular
(LV) preload, because the two ventricles are serially linked
through the pulmonary vasculature. LV preload can also be
directly altered by changes in RVEDV by the mechanism of
ventricular interdependence. The increased RVEDV in cor
pulmonale induces a shift of the interventricular septum into
the LV and decreases LV diastolic compliance but this does
not adversely affect LV SV because the increased RV systolic
pressure in cor pulmonale also pushes the septum into the
LV towards its free wall to empty the LV. This “help” from
the RV in systole tends to preserve LVEF in emphysematous
patients with severe RV hypertrophy [53, 54].
More importantly, hyperinflation, particularly during
exercise, has the effect of compressing the two ventricles into
each other [55, 56]. This decreases RV preload and results in
lower SV and CO. Even in less severe COPD the development
of hyperinflation during exercise can similarly lead to a
reduction in RV preload and CO.
During an acute exacerbation of COPD, the RV may
actually fail, that is, end-diastolic pressure and volume rise
and RVEF falls, resulting in peripheral edema and systemic
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congestion [57, 58]. However, these changes may not be
associated with a rise in PAP suggesting that other factors
may be operating to reduce RV contractility [57]. Moreover,
an acute exacerbation may be associated with peripheral
edema in the absence of RV failure [58].
The pathogenesis of edema formation in COPD is
complex. Renal blood flow is reduced, the renin-angiotensin
system is activated, renal dopamine output is reduced, and
plasma ANP level is elevated leading to increase in prox-
imal renal tubular sodium reabsorption [59, 60]. Sodium
retention is enhanced by hypercapnia and ameliorated by
long-term oxygen therapy in hypoxemic patients [61]. True
right heart failure is characterized by raised jugular venous
pressures, congestive hepatomegaly, and peripheral edema.
6. Degree of PH in COPD
Resting PH in stable COPD is usually mild to moderate
(mPAP 20–35 mm Hg) and is usually not seen until the
disease is advanced (FEV1 < 50%). Severe PH (mPAP > 35–
45 mm Hg) is rare (3%–13%) [5–7, 62] and should prompt
a search for an additional cause of PH, for example, left
heart disease, obstructive sleep apnea (OSA), pulmonary
embolism (PE).
6.1. Severe “Disproportionate” PH. Recently a group of pa-
tients with severe PH (mPAP > 40 mm Hg) and extremely
poor prognosis has been recognized. The 5-year survival is
15% versus 55% in those with less severe PH (mPAP 20–
40 mm Hg) [62]. Such patients are characterized by mild to
moderate airway obstruction, a very low diffusing capacity,
severe hypoxemia, and hypocapnia (Table 2) [62]. Thabut
et al. [6] have also described a similar group (mPAP >
45 mm Hg). However, such severe PH in COPD in the
absence of an alternative explanation is rare (1–3.7%) [6, 62]
and suggests the existence of a “vascular phenotype” or con-
comitant idiopathic pulmonary arterial hypertension.
7. Diagnosis of PH in COPD
PH secondary to COPD should be suspected in patients with
progressive dyspnea on exertion with stable airway obstruc-
tion or in patients with mild to moderate airway obstruction
with a very low diffusing capacity, severe hypoxemia, and
hypocapnia [6, 62].
A diagnosis of PH in COPD (Table 3) should prompt
a search for other causes of PH, particularly left heart dys-
function, OSA, and PE before attributing the PH to COPD.
7.1. Clinical Features. The clinical exam lacks sensitivity
and specificity. Hyperinflation reduces the yield of cardiac
auscultation for the classic signs of PH and right heart failure,
that is, loud P2, S3 gallop, the systolic murmur of tricuspid
regurgitation. Peripheral edema can be present in the absence
of right heart failure in COPD and is not diagnostic of right
heart failure.
7.2. CPET. Although cardiopulmonary exercise test (CPET)
characteristics show a large overlap in COPD patients with
and without PH, the existence of PH in COPD (defined as
mPAP > 25 mm Hg) is associated with a significantly reduced
ventilatory efficiency during CPET. However, a low SpO2 at
rest and a further decrease during exercise similarly suggest
the presence of PH in COPD [63].
7.3. Chest X-Ray. An increase in the diameter of the right de-
scending pulmonary artery to >16 mm on the PA projection,
combined with an increase in the diameter of the left de-
scending pulmonary artery of >18 mm on the left lateral
projection, has a sensitivity 98% for identifying PH [64].
7.4. ECG. Electrocardiographic criteria for the detection of
RV hypertrophy have good specificity, but the sensitivity for
RV hypertrophy is only 25 to 40%. The criteria include the
following: (a) right axis deviation (>100 degrees without
right bundle branch block), (b) R or R′ > S in V1, (c) R < S
in V6, (d) R in V1 + S in V5 or V6 = 10 mm, (e) R in V1 =
7 mm, (f) R in V1 = 15 mm with right bundle branch block,
and (g) right atrial enlargement [52].
However, ECG may reveal other findings such as
left atrial enlargement (LAE), left ventricular hypertrophy
(LVH), or myocardial infarction in the past that suggests an
alternative cause of PH.
The presence of S1 Q3 T3 (S wave in lead I, Q wave in
lead III, and T wave inversion in lead III on ECG—S1, Q3,
T3) or right atrial overload pattern (i.e., P wave axis of +90
degrees or more) implies a poor prognosis [65].
7.5. ECHO. Hyperinflation precludes optimal visualization
of the heart. In a cohort of lung transplant candidates estim-
ation of systolic PAP (sPAP) was possible in only 38% of
the 253 patients with COPD. Hyperinflation with a residual
volume >150% lessened the likelihood of sPAP estimation.
Sensitivity, specificity, negative predictive value (NPV), and
positive predictive value (PPV) of sPAP estimated by ECHO
for the diagnosis of PH (defined as sPAP >45 mm Hg esti-
mated by ECHO or measured by RHC) were 76, 65, 93, and
32%, respectively. In the absence of sPAP estimation, figures
for RV abnormalities were 84, 56, 96, and 22% respectively.
It is important to realize that there was a discordance of
>10 mm Hg between estimated and measured sPAP in 52%
of patients, and in 28%, the discordance was >20 mm Hg
[66]. Although the NPV of ECHO is high enough to exclude
PH when the heart is adequately visualized, the presence
of a high sPAP or RV abnormalities requires confirmation
by RHC unless the ECHO shows left heart disease, for
example, low LVEF, high LV filling pressure, LVH, left atrial
enlargement, valvular incompetence.
Alternatively, transcutaneous Doppler US can be used to
measure jugular vein flow velocity. Matsuyama et al. [67]
showed that the ratio of diastolic flow (Df) to systemic flow
(Sf) velocity showed a significant correlation with mPAP in
COPD patients (r = 0.844, P < 0.0001). The sensitivity was
71.4%, and the specificity 95.3% (cut-off ratio = 1.0). Jugular
venous Doppler US could be performed in all patients while
other cardiac echo methods could not be performed in all
patients. The specificity of the methods used was higher than
other cardiac echo methods [67].
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Table 2: Comparison of 2 groups of COPD patients with PH.
Severe PH Group (mPAP ≥ 40 mm Hg) N = 11 Less severe PH (mPAP 20–40 mm Hg) N = 16 P value
FEV1 (% predicted) 50 (44–56) 27 (23–34) <0.01
DLCO (mL/min/mm Hg) 4.6 (4.2–6.7) 10.3 (8.9–12.8) <0.01
PaO2 (mm Hg) 46 (41–53) 56 (54–64) <0.01
PaCO2 (mm Hg) 32 (28–37) 47 (44–49) <0.01
RAP (mm Hg) 7 (5–9) 3 (1.3–4) <0.01
mPAP (mm Hg) 48 (46–50) 25 (22–27) <0.01
PAWP (mm Hg) 6 (4–7) 7 (6.5-7.5) NS
CI (L/min/m2) 2.3 (1.8–2.5) 2.8 (2.4–3.1) <0.01
TPR (Wood units/m2) 21.3 (17.6–26.6) 9 (7.4–9.9) <0.01
Table adapted from [63].
PH: pulmonary hypertension, FEV1: forced expiratory volume in the first second, DLCO: diffusing capacity for carbon monoxide, PaO2: arterial oxygen
tension, PaCO2: arterial carbon dioxide tension, RAP: right atrial pressure, mPAP: mean pulmonary artery pressure, CI: cardiac index, TPR: total pulmonary
resistance.
Table 3: Various approaches to the diagnosis of PH in COPD.
Modality Advantages Disadvantages
ECG
Noninvasive, cheap, and readily available.
High specificity for RVH.
ECG may reveal other findings such LAE, LVH, or old MI that suggests an
alternative cause of PH
Absence of RVH does not rule out PH.
CXR
Non-invasive, cheap, and readily available.
An ↑ in the diameter of the right descending pulmonary artery to
>16 mm on the PA projection, combined with an ↑ in the diameter of the
left descending pulmonary artery of >18 mm on the left lateral projection,
has a high sensitivity of 98% for PH
Normal-sized pulmonary artery does not rule
out PH.
BNP Requires only a blood draw, is cheap and readily available.
↑ BNP also correlated with lower PaO2
suggesting that BNP can also be released in
response to hypoxia. More studies are needed.
eNO Non-invasive.
Expensive, not widely available and has been
tested in only one study.
ECHO
High NPV of sPAP or RV abnormalities (93% and 96%, resp.) makes it an
excellent screening test.
Moreover, it provides additional data for example, LVEF, LV filling
pressures, valvular function.
Hyperinflation may preclude optimal
visualization of the heart.
Although the NPV is high enough to exclude
PH, the presence of a high sPAP or RV
abnormalities requires confirmation by RHC.
Chest CT
Non-invasive, widely available.
High PPV of 95%-96% for PH.
LAE could suggest left heart dysfunction.
Expensive.
Radiation exposure.
Normal sized pulmonary artery does not rule
out PH.
Cardiac MRI
Non-invasive, does not involve ionizing radiation, and is not affected by
hyperinflation.
Expensive, not widely available and in some





Distinguishes occult LV dysfunction from hyperinflation when PAWP is ↑.
Measures CO and allows calculation of PVR.
Determines responsiveness to O2.
Invasive.
Interpretation of pressures may be difficult
when there are large respiratory swings.
PH: pulmonary hypertension, EKG: electrocardiography, RVH: right ventricular hypertrophy, LAE: left atrial enlargement, LVH: left ventricular hypertrophy,
MI: myocardial infarction, CXR: chest X-ray, BNP: brain natriuretic peptide, PaO2: arterial oxygen tension, eNO: exhaled nitric oxide, NPV: negative predictive
value, ECHO: echocardiography, sPAP: systolic pulmonary artery pressure, RV: right ventricular, LVEF: left ventricular ejection fraction, LV: left ventricular,
RHC: right heart catheterization, CT: computerized axial tomography, PPV: positive predictive value, MRI: magnetic resonance imaging, CO: cardiac output,
PVR: pulmonary vascular resistance, PAWP: pulmonary artery wedge pressure, RAP: right atrial pressure, O2: oxygen.
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Table 4: Various approaches to the treatment of PH in COPD.
Counteract hyperinflation Counteract pulmonary vasoconstriction Counteract vascular remodeling Counteract polycythemia
Bronchodilators O2 O2 O2
O2 Pulmonary vasodilators Pulmonary vasodilators Phlebotomy
Sildenafil Statins ARB
LVRS (unless PH severe)
Lung transplantation
Smoking cessation
PH: pulmonary hypertension, O2: oxygen, LVRS: lung volume reduction surgery, ARB: angiotensin receptor blocker.
7.6. BNP. One study of 38 patients with stable COPD, 20 of
whom had clinical cor pulmonale, found significant correla-
tion between brain natriuretic peptide (BNP) and ECHO-
estimated sPAP (r = 0.68, P = 0.001) [68]. Elevated BNP
also correlated with lower PaO2 suggesting that BNP can also
be released in response to hypoxia.
7.7. Exhaled Nitric Oxide. Clini et al. [69] studied 34 con-
secutive patients with stable COPD and found that patients
with PH (defined as ECHO-estimated sPAP of >35 mm Hg)
showed lower values of exhaled nitric oxide compared to
those without PH.
7.8. Cardiac MRI. This imaging technique produces excel-
lent images of the RV and RV wall thickness shows a high
correlation with the mean PAP (r = 0.9; P < 0.001) [70].
Moreover, it offers many advantages: it is non-invasive, does
not involve radiation, and is not affected by hyperinflation.
However, it is expensive, not widely available and in some
cases claustrophobia can preclude its use.
7.9. Chest CT Scan. Enlargement of the main pulmonary
artery to ≥29 mm in patients with parenchymal lung disease
has been shown to have a sensitivity of 84%, specificity of
75%, PPV of 95%, and positive LR of 3.36 for predicting PH
(defined as mPAP > 20 mm Hg) [71].
In another study the ratio of the pulmonary artery to
aortic diameter >1 was 70% sensitive and 92% specific for
PH (defined as mPAP > 20 mm Hg). The PPV was 96% and
the NPV was 52% [72].
Moreover, an increased left atrial area on chest CT could
suggest left heart dysfunction as a possible cause of PH [73].
7.10. Right Heart Catheterization. RHC remains the “gold
standard” for making a diagnosis of PH, accurately deter-
mining its severity, and ruling out left heart disease, espe-
cially occult LV diastolic dysfunction. An elevated PAWP is
not uncommon in severe COPD and does not necessarily
imply LV dyfunction [5] as it may be secondary to hyper-
inflation [21]. Exercise during RHC can help distinguish the
cause of an elevated PAWP in COPD. PAWP increases out of
proportion to right atrial pressure (RAP) during exercise in
comparison to hyperinflation where PAWP and RAP increase
proportionately during exercise [74]. Moreover, RHC also
measures CO and allows calculation of PVR. Lastly, RHC
Table 5: Various pulmonary vasodilators studied for the treatment




O2 CCB: nifedipine, felodipine PDE5 I: sildenafil
NO α-1 antagonist: prazosin ETRA: bosentan
PG: iloprost ACEI: captopril
PH: pulmonary hypertension, O2: oxygen, NO: nitric oxide, PG: prostaglan-
din, CCB: calcium channel blocker, ACEI: angiotensin converting enzyme
inhibitor, PDE5 I: phosphodiesterase 5 inhibitor, ETRA: endothelin receptor
antagonist.
allows determination of responsiveness to O2. However,
the invasive nature of the procedure precludes its more
widespread use.
8. Natural History of PH in COPD
Kessler et al. [75] studied 131 patients with COPD (mean
FEV1 44.6 ± 15.7%) with mild to moderate hypoxemia
(PaO2 > 60 mm Hg) and without resting PH (mPAP <
20 mm Hg). FEV1 was <35% in 28%, 35–49% in 45%,
and ≥50% in 26%. Approximately 25% of the patients
developed resting PH during a 6-year followup (mean mPAP
26.8±6.6 mm Hg). More importantly, twice as many patients
with exercising PH at the onset developed resting PH over
time (32% versus 16%). The average change in mPAP was
0.4 mm Hg per year. Patients with accelerated worsening
of resting mPAP differed by a significant worsening of
exercising mPAP whereas the changes of FEV1 and PaO2 were
rather similar. Moreover, patients who developed resting PH
had higher resting and exercising mPAP and significantly
lower resting and exercising PaO2 at baseline [75].
9. Treatment of PH Secondary to COPD
The adverse effect of PH on survival and exercise capacity,
and the increased risk of severe acute exacerbations caused by
PH provide the rationale for treating PH in COPD. The goals
of treatment, therefore, are to improve survival, improve
exercise tolerance, reduce exacerbations, and improve quality
of life. Various approaches to the treatment of PH in COPD
are listed in Table 4. Various pulmonary vasodilators used in
the treatment of PH in COPD are listed in Table 5.
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10. Oxygen
LTOT improves survival in stable COPD patients with resting
hypoxemia (PaO2 < 55 mm Hg) and is associated with a mild
improvement in pulmonary hemodynamics [76, 77].
In the Medical Research Council trial (N = 87), mortality
rate at 5 years was 67% in the no-O2 group and 45% in the
O2-treated group (15 h/day). In patients alive at 500 days
who received repeat RHC, mPAP increased in the no-O2
group (n = 21) at an average rate of 2.7 mm Hg/year and
remained unchanged in the O2-treated group (n = 21) [76].
In the Nocturnal Oxygen Therapy (NOT) Trial (N = 200),
the mortality rate after 1 year was 11.9% in the continuous
O2 therapy group (averaging 17 h/day) and 20.6% in the
nocturnal O2 therapy group (averaging 12 h/day). In patients
undergoing hemodynamic measurement at baseline and 6
months after enrollment (n = 117), mPAP showed a slight
rise in the nocturnal O2 therapy group and a slight fall
(at an average of 3 mm Hg/year) in the continuous O2
therapy group. PVR decreased by 11.1% in the continuous
O2 therapy group but increased by 6.5% in the nocturnal O2
therapy group [78].
Unfortunately not all patients with COPD who meet cri-
teria for LTOT benefit from it. Ashutosh et al. [79] showed
that patients who exhibited a significant drop in mean PAP of
≥5 mm Hg after acute O2 therapy (28% for 24 h) had an 88%
2-year survival compared to 22% in nonresponders when
both groups of patients were subsequently treated with con-
tinuous LTOT [79]. Of note, room air VO2 max provided the
same information in that study with 6.5 mL/kg/min being the
cut-off that distinguished responders from nonresponders
[79].
Similarly, even in the landmark NOT trial O2 therapy
resulted in an improved survival only in patients whose base-
line SVI was >30 mL/beat/m2 (in the continuous O2 group)
or PVR was <400 dyne·s·cm−5 (in the nocturnal O2 group)
[78].
Weitzenblum et al. who followed up 16 hypoxemic
COPD patients on LTOT for a period of 6 years demonstrated
a reversal but not normalization of the PAP [15].
Moreover, supplemental O2 during exercise decreases
PAP and increases exercise tolerance even in COPD patients
with mild resting hypoxemia (PaO2 > 60 mm Hg) and mode-
rate-to-severe airflow obstruction [80]. This effect was found
to be the result of inhibition of hypoxic pulmonary vaso-
constriction and reduction in air trapping (indicated by the
difference in slow and forced vital capacity). Others have also
shown that supplemental O2 reduces dynamic hyperinflation
and consequently the PAP and PAWP [20, 81]. Supplemental
O2 during exercise also improves RV function [82].
Lastly, O2 therapy abolishes the nocturnal rise in PAP
acutely [83] as well as decreases PAP in the long-term in
COPD patients with PH and daytime PaO2 > 60 mm Hg who
experience nocturnal desaturation [84].
11. Nonspecific Pulmonary Vasodilators
Various vasodilators: calcium channel blockers, β2-agonists,
nitrates, angiotensin converting enzyme inhibitors, and
α1-antagonists were studied in the 80s. Most of them caused
a modest decrease in mPAP accompanied by an increase in
CO and a decrease in PVR but they were also associated
with systemic hypotension and worsening of ventilation-
perfusion mismatch that in some cases was not offset by the
increase in CO [85].
12. Specific Pulmonary Vasodilators
The recent discovery of endothelial dysfunction resulting in
the altered production of mediators of tone and/or prolif-
eration, and consequently pulmonary vasoconstriction and
vascular remodeling, provides the rationale for considering
specific pulmonary vasodilators that also possess antiprolif-
erative properties.
12.1. Inhaled Nitric Oxide. Inhaled nitric oxide (iNO) is a
more potent vasodilator than O2. However, when used alone
iNO worsens ventilation-perfusion imbalance. In a random-
ized controlled trial (RCT) 40 patients with severe COPD
(mean FEV1 1.19 ± 0.6 L) and PH (mPAP > 25 mm Hg)
who were receiving LTOT were randomized to pulsed iNO
(delivered via a novel device NOXXI; Messer, Austria) plus
O2 or O2 alone for 3 months [86]. There was a significant
improvement in mPAP, PVR, and CO. The mPAP decreased
from 27.6 to 20.6 mm Hg (P < 0.001); PVR decreased from
276.9 to 173 dyne·s·cm−5 (P < 0.001). Systemic hemody-
namics and left heart function remained unchanged. PaCO2
decreased significantly in the treatment group, suggesting
improved perfusion of the better ventilated areas. Significant
methemoglobinemia was not seen. Although this study
shows a promising role for iNO in stable COPD patients with
PH, it is important to realize that iNO needs to be delivered
in a pulsed manner to limit the formation of nitrogen dioxide
and to avoid worsening ventilation-perfusion mismatch, and
such delivery requires a more practical device.
12.2. Inhaled Iloprost. In a study by Dernaika et al. [87] 10
males with FEV1 < 65% with Pa O2 60–75 mm Hg and PH
(defined as sPAP > 35 mm Hg plus RV dilatation and/or
RV hypertrophy on ECHO) were evaluated before and after
inhaling 2 doses of iloprost (2.5 μg). PFT, ABG, 6MWT
and ventilatory equivalents for O2 (VE/VO2) and CO2
(VE/VCO2) were performed at baseline, 30 min following
each dose of iloprost, and 2 h after the second dose. Iloprost
was associated with improved ventilation-perfusion match-
ing and exercise tolerance. The 6MWD increased by 49.8 ±
35 m (P = 0.02).
12.3. Lessons Learnt from the Trials of Inhaled Pulmonary Vas-
odilators. In patients with severe COPD and resting mPAP >
25 mm Hg inhaled NO and O2 improve pulmonary hemo-
dynamics and ventilation-perfusion mismatch. The recent
development of a lightweight (approximately 4 kg) and por-
table pulsed delivery system INOpulse DS, that also elim-
inates the need for calibration or monitoring of NO or
NO2, offers the possibility of using inhaled NO in COPD
patients with PH. However, this promising device has not
been studied in COPD or PH.
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In patients with COPD with FEV1 < 65% and ECHO-
estimated resting sPAP > 35 mm Hg iloprost alone improves
ventilation-perfusion mismatch and 6MWD. However, its
effects last only 2 hours. Another inhaled prostaglandin tre-
prostinil, which is now available and has a longer duration
of action, may be a more feasible option. However, it has not
been studied in COPD.
12.4. Sildenafil. Alp et al. [88] were the first to report on
the acute and long-term effects of sildenafil in COPD. They
showed that in 6 patients with COPD with FEV1 < 50% and
PH (mPAP 29.5 ± 5.2 mm Hg) sildenafil 50 mg IV, once fol-
lowed by 50 mg PO BID for 3 months, resulted in significant
improvement in both hemodynamics and 6MWD. The mean
6MWD increased by 82 m (from 351±49 to 433±52 m) after
3 months.
However, Holverda et al. [89] failed to show similar
results in two studies. They studied the acute effects of a
single oral dose of sildenafil 50 mg in 18 patients with GOLD
stage II–IV and showed that regardless of the mPAP at rest,
sildenafil attenuated the increase in mPAP during submaxi-
mal exercise but this was neither accompanied by enhanced
SV and CO, nor by improved exercise capacity. However,
only 11 patients had PH: 5 at rest (mPAP > 25 mm Hg) and
6 with PH on exercise (mPAP > 30 mm Hg).
The same group went on to study the effects of sildenafil
50 mg PO TID for 3 months in 15 patients with GOLD stage
II–IV and reported similar results—neither SV nor exercise
capacity improved [90]. However, again, not all patients had
PH—only 9 had PH: 5 at rest (mPAP > 25 mm Hg) and 4 on
exercise (mPAP > 30 mm Hg).
In a randomized dose comparison trial of sildenafil 20
versus 40 mg in 20 patients with COPD and resting PH
(mPAP > 20 mm Hg) both doses improved pulmonary
hemodynamics at rest and during exercise but this was
accompanied by worsening hypoxemia albeit only at rest
[91]. Interestingly, there was also noted to be a slight but
statistically significant improvement in FEV1 and forced
vital capacity (FVC). Although such a bronchodilatory effect
of sildenafil has also been reported in two patients in the
literature [92] and is probably mediated through its inhi-
bition of the phosphodiesterase-5 enzyme [93], it has not
been evaluated in a controlled manner.
On the other hand, in a double blind RCT of 33 patients
with severe COPD and ECHO-estimated sPAP > 40 mm Hg
Rao et al. [94] showed that the median 6MWD improved by
191 m and sPAP by 12 mm Hg after sildenafil 20 mg PO TID
for 3 months (P < 0.05).
12.5. Bosentan. In a double blind RCT of 30 patients with
severe to very severe COPD Stolz et al. [95] showed that
bosentan 125 mg PO BID for 3 months not only failed to
improve exercise capacity but also deteriorated hypoxemia
and functional status. It is important to keep in mind that
only 14 of 20 patients in the bosentan group and 6 of 10
patients in the placebo group had PH at rest (defined as
ECHO-estimated sPAP > 30 mm Hg without adding central
venous pressure).
On the contrary, in another RCT, this one of 40 patients
with COPD and PH (mPAP > 25 mm Hg and PAWP <
15 mm Hg), Valerio et al. [96] showed that bosentan 125 mg
PO BID for 18 months resulted in a significant improvement
in hemodynamics, 6MWD and BODE index: mPAP from
37± to 31 ± 6 mm Hg, PVR from 442 ± 192 to 392 ±
180 dyne·s·cm−5, 6MWD from 256 ± 118 to 321 ± 122 m,
and BODE index from 6.6±2.8 to 5.5±3 units. Most patients
in stage IV, who made up 30% of the study population and
were characterized by high BODE index, WHO functional
class IV, no reversibility with O2, and higher increases in PAP
and PVR during exercise, did not improve but in all such
patients the treatment stopped the progressive worsening of
hemodynamics.
12.6. Lessons Learnt from the Trials of Oral Specific Pulmonary
Vasodilators (Tables 6 and 7). In patients with severe COPD
and resting mPAP < 25 mm Hg pulmonary vasodilator ther-
apy may improve PAP during exercise but does not improve
SV and CO or exercise capacity. This is probably because
hyperinflation plays a predominant role in the pathophys-
iology of reduced SV and CO in such patients (Figure 3).
Severe hyperinflation with inspiratory capacity to total lung
capacity (IC/TLC) ratio <25% causes a “tamponade” effect
on the heart and reduces RV preload [55, 56, 97] whereas any
reduction in RV afterload that may result from pulmonary
vasodilatation is of no avail and the SV is limited particularly
during exercise. Therefore, pulmonary vasodilators should
be neither studied nor used in COPD patients with mild
resting PH (mPAP < 25 mm Hg or ECHO-estimated sPAP <
40 mm Hg) or in COPD patients with PH only on exercise.
On the other hand, in patients with COPD and resting
mPAP > 25 mm Hg or ECHO-estimated sPAP > 50 mm Hg
pulmonary vasodilator therapy improves pulmonary hemo-
dynamics and 6MWD. However, more research is needed to
recommend the use of pulmonary vasodilators in PH sec-
ondary to COPD. Although COPD patients with severe PH
(mPAP > 35–45 mm Hg) who probably represent a “vascular
phenotype” or have concomitant IPAH will benefit the most
from pulmonary vasodilator therapy, it may be worthwhile
to try such therapy in COPD patients with less severe PH
(mPAP 25–35 mm Hg) especially if hyperinflation is not
playing a significant role. Although it has not been evaluated,
pulse oximeter plethysmography waveform analysis to iden-
tify “pulsus paradoxus” may be a simpler way of identifying
patients with severe hyperinflation with IC/TLC ratio <25%.
It is important to keep in mind that even specific pul-
monary vasodilators can worsen ventilation-perfusion mis-
match and hypoxemia at rest that may or may not be offset
by an increase in CO. Lastly, lack of acute responsiveness to
pulmonary vasodilators indicates a more altered vasculature
that may respond to a longer course of therapy or to statins.
13. Statins
Statins have anti-inflammatory, antioxidant, and antithrom-
bogenic effects and restore endothelial function [98]. More-
over, statins can reduce the synthesis of ET-1 at the trans-
criptional level [99].
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Table 6: Summary of the effects of pulmonary vasodilators in the published studies of such drugs in COPD patients.
First author Alp et al. [88] Holverda et al. [89] Rietema et al. [90] Stolz et al. [95] Valerio et al. [96] Blanco et al. [91] Rao et al. [94]
Year of publication 2006 2008 2008 2008 2009 2010 2011
Country Germany Netherlands Netherlands Switzerland Italy Spain India
Drug Sildenafil Sildenafil Sildenafil Bosentan Bosentan Sildenafil Sildenafil
Dose 50 mg BID 50 mg 50 mg TID 125 mg BID 125 mg BID 20 mg vs 40 mg 20 mg TID
Duration 3 months Acute effects 3 months 3 months 18 months Acute effects 3 months
Total N 5 18 15 20 20 20 17
N with PH 5 11 9 14 20 12 17
N with resting PH 5 5 5 14 20 12 17
PAP ↓ ↓ r + e No Δ ↓ ↓ r + e ↓
CO NA No Δ r + e No Δ r + e No Δ No Δ ↑ r + e
PVR ↓ No Δ r + e No Δ ↓ ↓ r + e
SpO2PaO2 ↓ r + e No Δ r + e ↓ r, No Δ e No Δ ↓ r, No Δ e
6MWD (m) at
baseline
351 ± 49 385 ± 135 339 ± 81 257 ± 150 396 ± 114 269 ± 140
6MWD (m) after
treatment
↑ to 433 ± 52 ↑ to 396 ± 116 ↑ to 329 ± 94 ↑ to 321 ± 122 NA ↑ by 191 ± 127
mg: milligrams, BID: twice a day, TID: three times a day, vs: versus, N: total number of patients who received the study drug, N with PH: number of patients
with pulmonary hypertension, PH: pulmonary hypertension, PAP: pulmonary artery pressure, CO: cardiac output, PVR: pulmonary vascular resistance,
SpO2: oxygen saturation by pulse oximetry, PaO2: arterial oxygen tension, 6MWD: six-minute walk distance, m: meters, NA: not available or not applicable,
r + e: rest and exercise, Δ: change, r: rest, e: exercise.
Table 7: Baseline characteristics of the patients who received pulmonary vasodilators in the published studies of such drugs in COPD.
First author Alp et al. [88] Holverda et al. [89] Rietema et al. [90] Stolz et al. [95] Valerio et al. [96] Blanco et al. [91] Rao et al. [94]
Year of publication 2006 2008 2008 2008 2009 2010 2011
Drug Sildenafil Sildenafil Sildenafil Bosentan Bosentan Sildenafil Sildenafil
Dose 50 mg BID 50 mg 50 mg TID 125 mg BID 125 mg BID 20 mg vs 40 mg 20 mg TID
Duration 3 months Acute effects 3 months 3 months 18 months Acute effects 3 months
Total N 5 18 15 20 20 20 17
N with PH 5 11 9 14† 20 12 17
N with resting PH∗ 5 5 5 14† 20 12 17
Age (years) 45–64 66 ± 9 65 ± 2 69.5 ± 8.8 66 ± 9 64 ± 7 60 ± 7
sPAP (mm Hg) 32‡ 53 ± 12
mPAP (mm Hg) 29.5± 5.2 23 ± 10 22 ± 9 37± 5 27± 10 33.8 ± 9.2§
CO (L/min)
5.5 ± 1.0 5.4 ± 1.7 2.45 ± 0.4 2.8 ± 0.7 4.9 ± 0.95
CI (L/min/m2) 2.7 ± 0.44
PVR (dynes.s.cm-5) 373 ± 118 280 ± 180 259 ± 166 158 ± 30 442 ± 192 339 ± 165
FEV1 (% predicted) 16–48 52 ± 26 49 ± 24 38 ± 13 37 ± 18 35 ± 11 32.5 ± 11
TLC (% predicted) 126 ± 15 125 ± 16 126 ± 15 132 ± 6 114 ± 19
DLCO (% predicted) 46 ± 17 48 ± 16 37 ± 18 34 ± 7 44 ± 17
SpO2 (%) 93 ± 4 95 ± 2 93 ± 3
PaO2 (mm Hg) 74 ± 13 57 ± 10 64 ± 11
PaCO2 (mm Hg) 39 ± 6 46 ± 8 38.4 ± 4.5
6MWD (meters) 351 ± 49 385 ± 135 339 ± 81 257 ± 150 396 ± 114 269 ± 140
mg: milligrams, BID: twice a day, TID: three times a day, vs: versus, N: total number of patients who received the study drug, N with PH: number of
patients with pulmonary hypertension, PH: pulmonary hypertension, sPAP: systolic pulmonary artery pressure estimated by echocardiography, mPAP: mean
pulmonary artery pressure measured by right heart catheterization, CO: cardiac output, CI: cardiac index, PVR: pulmonary vascular resistance, FEV1: forced
expiratory volume in the first second, TLC: total lung capacity, DLCO: diffusing capacity for carbon monoxide, SpO2: oxygen saturation by pulse oximetry,
PaO2: arterial oxygen tension, PaCO2: arterial carbon dioxide tension, 6MWD: six-minute walk distance.
∗resting PH defined as mPAP > 25 mm Hg or ECHO estimated sPAP > 40 mm Hg unless specified otherwise—see below:
†PH was defined as estimated sPAP > 30 mm Hg without adding central venous pressure (CVP).
‡Estimated sPAP without adding CVP. If CVP is assumed to be 5 mm Hg, this gives a sPAP of 37 mm Hg which amounts to a mPAP of 24 mm Hg based on
the prediction equation 0.6 × sPAP + 2 = mPAP [113].

















Figure 3: Pathophysiology of reduced SV in COPD. SV: stroke volume, PVR: pulmonary vascular resistance, RV: right ventricular, LV: left
ventricular, PEEP: positive end-expiratory pressure.
In a double-blind parallel design study [100], 53 patients
with COPD and ECHO-estimated sPAP > 35 mm Hg were
randomly assigned to receive either pravastatin 40 mg daily
or placebo for 6 months. Exercise time increased significantly
52% from 660 ± 352 to 1006 ± 316 seconds (P < 0.0001)
in the treatment group. ECHO-estimated sPAP decreased
significantly from 47 ± 8 to 40 ± 6 mm Hg. There was also
significant improvement in Borg dyspnea score.
In an animal study, Wright et al. [101] studied the effects
of simvastatin in guinea pigs exposed to cigarette smoke for
6 months. In half of the animals simvastatin was introduced
after 3 months. Cigarette smoke increased the sPAP after
approximately 4 weeks. Simvastatin returned the pressure
to control levels within 4 weeks of starting treatment, and
ameliorated smoke-induced small arterial remodeling as well
as emphysema measured both physiologically and mor-
phometrically at 6 months, but did not prevent smoke-
induced small airway remodeling either physiologically or
morphologically. In precision-cut lung slices simvastatin
reversed small arterial endothelial dysfunction and partially
reversed smoke-induced loss of vascular NO generation.
Both studies show prospects for the use of statins in
COPD and warrant more research.
14. Diuretics
Diuretics reduce right ventricular dilatation and improve its
contractility and also reduce extravascular lung water [102].
They should be used cautiously as they can cause intra-
vascular volume depletion that may deprive the RV of ade-
quate preload to maintain a normal SV.
15. Phlebotomy
Phlebotomy is usually indicated in patients with polycyth-
emia not responding to LTOT. In a small study of 7 patients
with stable severe COPD (FEV1 33 ± 3% of predicted) and
PH, Borst et al. [103] showed that isovolemic phlebotomy
resulted in improvement in pulmonary hemodynamics,
gas exchange, and exercise tolerance. The patients were
phlebotomized 5-6 times over a period of 3 months with
substitution of 6% hydroxyethyl starch (molecular weight
40,000). This resulted in a stepwise reduction of the hema-
tocrit from 53.3 ± 2.6 to 45.8 ± 3.1%. Mean PAP decreased
from 30±3 to 22±2 mm Hg and PaO2 increased from 63.2±
2.2 to 71.8± 3.7 mm Hg at rest. During peak exercise, mPAP
decreased from 59± 7 to 53 ± 7 mm Hg and PaO2 increased
from 54.0 ± 5.7 to 63.2 ± 2.4 mm Hg after hemodilution.
Peak oxygen consumption rose from 573 ± 84 to 750 ±
59 mL/min, corresponding to an increase in CI from 4.25 ±
0.5 to 5.88 ± 0.76 liters/min/m2. PVR fell from 345 ± 53 to
194 ± 32 dyne·s·cm−5. The patients’ peak exercise capacity
increased from 9.2± 2.0 before to 13.5± 3.2 kJ at the end of
the study (P < 0.05 for all differences).
16. “Bloodless Phlebotomy”
Activation of the renin-angiotensin system may contribute
to polycythemia in COPD [104]. Plasma renin and aldos-
terone levels are increased in such patients when matched
with controls for hypoxemia. The mechanism of action
is serum-erythropoietin-independent. In a small study, the
angiotensin receptor blocker (ARB) losartan was used in
weekly escalating doses to a maximum of 100 mg daily for
4 weeks in 9 stable severe COPD patients with polycythemia
(hematocrit >52%). The regimen caused a significant reduc-
tion in the hematocrit of all patients from 56 ± 0.9% to
46 ± 0.7% (P < 0.001). The higher the baseline value, the
greater the reduction in hematocrit (r = 0.7085; P < 0.05)
[105]. At 3 months after discontinuation of losartan the
hematocrit increased to 50 ± 0.7%. Similarly, in an RCT of
60 patients with severe COPD another ARB irbesartan also
induced a significant reduction in hematocrit [106]. Of note,
however, neither study evaluated pulmonary hemodynamics,
gas exchange or exercise tolerance which makes it difficult to
draw any meaningful conclusions.
Although it is tempting to speculate that such a “blood-
less” phlebotomy may also result in improvement in pul-
monary hemodynamics, gas exchange, and exercise tol-
erance, it is important to realize that ARBs are also
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non-specific vasodilators that can cause a modest decrease
in mPAP as well as worsen PaO2. In fact in a double-blind
RCT of COPD patients with transtricuspid pressure gradient
(TTPG) >30 mm Hg more patients in the losartan group
(50%) than in the placebo group (22%) showed a clinically
meaningful reduction in TTPG at any time point during the
12-month period, and these effects seemed more marked in
patients with higher baseline TTPG. There were no clear
improvements in exercise capacity or symptoms, though
[107].
17. Lung Volume Reduction Surgery (LVRS)
Although lung volume reduction surgery (LVRS) is contra-
indicated in COPD patients with severe PH (mPAP >
35 mm Hg), the reduction in hyperinflation and improve-
ment in gas exchange resulting from such surgery are
expected to result in an improvement in PAP in patients
with less severe PH. On the other hand excision of some
viable pulmonary vascular bed may have the adverse effect of
worsening PVR. In fact the few studies of pulmonary hemo-
dynamics before and after LVRS have shown that the mPAP
remains unchanged after such surgery [108–111]. Earlier
and smaller studies showed that mPAP remains unchanged
because CO improves when PVR falls after LVRS [108–110].
In contrast, the most recent and largest study of pulmonary
hemodynamics before and after LVRS, which was a cardiac
substudy of the national emphysema treatment (NET) trial,
did not show any significant change in CO [111]. Reasons for
the discrepancy between the results of the earlier studies and
the NET trial are not clear, but could be due to differences
in patient selection, or surgical methods. Moreover, unlike
the other studies, the NET trial did not evaluate pulmonary
hemodynamics during exercise.
18. Lung Transplantation
PH secondary to COPD is an indication for lung transplanta-
tion. Bjortuft et al. [112] investigated a group of 24 patients,
including 19 with COPD, who underwent single lung trans-
plantation. The majority (15 out of 24) of patients had mild-
to-moderate PH at the onset and in these patients mPAP
significantly decreased from 28 ± 1 to 18 ± 1 mm Hg after
transplantation; there was a similar decrease in PVR. These
results were maintained after 2 yrs of followup. Therefore,
COPD patients with PH normalize pulmonary haemody-
namics after single lung transplantation.
19. Conclusion
The pathophysiology of PH in COPD is complex. A diagnosis
of PH in COPD should prompt a search for other causes
of PH, particularly left heart dysfunction, OSA, and PE
before attributing the PH to COPD. PH in COPD adversely
affects survival and exercise capacity and is associated with an
increased risk of severe acute exacerbations. Unfortunately
not all patients with COPD who meet criteria for LTOT
benefit from it. Even in those who benefit from LTOT,
such therapy may reverse PAP but cannot normalize it.
Moreover, the recent discovery of the key roles of endothelial
dysfunction and inflammation in the pathogenesis of PH
provides the rationale for considering specific pulmonary
vasodilators that also possess antiproliferative properties and
statins. Studies of pulmonary vasodilators and statins for
PH secondary to COPD appear to show a promising role
for such therapy in patients with more than mild PH
(mPAP > 25 mm Hg) and warrant more research. Success of
pulmonary vasodilator therapy appears to depend upon the
degree of PH and the severity of hyperinflation. Such therapy
is more likely to be successful when PH is moderate to severe
(mPAP > 25 mm Hg) and hyperinflation is not playing a
significant role, that is, IC/TLC is >25%. Although stable
COPD patients with severe PH (mPAP > 35–45 mm Hg)
who probably represent a “vascular phenotype” or have
concomitant IPAH warrant pulmonary vasodilator therapy,
it may be worthwhile to try such therapy in stable COPD
patients with less severe PH (mPAP 25–35 mm Hg) especially
if hyperinflation is not severe. On the other hand such
therapy should be avoided when PH is mild or only during
exercise or hyperinflation is playing a significant role, that is,
IC/TLC is <25%. Future studies of pharmacotherapy should
focus on patients with PH with mPAP > 25 mm Hg and
IC/TLC > 25%.
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